HMS LINCS Batch ID,HMS LINCS ID,Name,Alternative Names,LINCS ID,Alternative ID,Reference Source,Organism,Organ,Tissue,Cell Type,Details of Cell Type,Donor Sex,Donor Age,Donor Ethnicity,Donor Health Status,Disease,Details of Disease,Production Details,Genetic Modification(s),Known Mutations,Citation Information for Mutations,Verification Reference Profile,Growth Properties,Recommended Culture Conditions,Relevant Citations,Usage Note,Comments,Provider,Provider Catalog ID,Provider Batch ID,Source Information,Date Received,HMS QC Outcome,Transient Modification(s),Date Publicly Available,Most Recent Update
50001-2,50001,5637,,LCL-1702,"CLO_0001421","ATCC HTB-9",Homo sapiens,urinary bladder,,epithelial,,male,,,,"DOID:4007, bladder carcinoma",,,none,,"COSS687452","DNA Profile (STR, source: ATCC):
Amelogenin: X,Y
CSF1PO: 11
D13S317: 11
D16S539: 9
D5S818: 11,12
D7S820: 10,11
THO1: 7,9
TPOX: 8,9
vWA: 16,18",adherent,"From MGH/CMT as specified by cell provider: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%. Protocol: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation ratio: A subcultivation ratio of 1:4 to 1:8 is recommended",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-6,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-04-04
50002-1,50002,647-V,,LCL-1708,"CLO_0001450","Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures ACC 414",Homo sapiens,urinary bladder,,epithelial-like,,male,,,,"DOID:4007, bladder carcinoma; DOID:4006, bladder transitional cell carcinoma",transitional cell carcinoma; urothelial bladder carcinoma,,none,,"COSS906797",,adherent,From MGH/CMT as specified by cell provider: 85% Dulbecco's MEM + 15% FBS + 2 mM L-glutamine split confluent culture 1:5 to 1:6 every 3-4 days using trypsin/EDTA; seed out at ca. 2 x 106 cells/80 cm 2 in 10 ml medium at 37C with 5-10% CO2 cell harvest of ca. 10-15 x 106 cells/175 cm 2,,,,,,,,,,,2012-04-25,2016-08-24
50003-1,50003,A375.S2,,LCL-1231,"CLO_0001583","ATCC CRL-1872",Homo sapiens,skin,,epithelial,,female,,,,"DOID:1909, malignant melanoma",,,none,,,"DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 11,12
D13S317: 11,14
D16S539: 9
D5S818: 12
D7S820: 9
THO1: 8
TPOX: 8,10
vWA: 16,17",adherent,"From MGH/CMT as specified by cell provider: Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%.
Subculturing: Remove medium, rinse with fresh 0.25% trypsin, 0.03% EDTA solution and let the culture sit at room temperature (or 37C) until cells detach (about 10 minutes). Add fresh medium, aspirate and dispense into new flasks.
Subcultivation ratio: A subcultivation ratio of 1:3 to 1:8 is recommended",,,,,,,,,,,2012-04-25,2016-07-12
50004-1,50004,AGS,,LCL-1893,"CLO_0001686","ATCC CRL-1739",Homo sapiens,stomach,,epithelial,,female,,,,"DOID:5517, stomach carcinoma; DOID:3717, gastric adenocarcinoma",,,none,,"COSS906790",,adherent,"From MGH/CMT as specified by cell provider: Ham's F12K medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 90%; fetal bovine serum, 10%",,,,,,,,,,,2012-04-25,2016-04-04
50006-1,50006,Ca Ski,CaSki,LCL-1541,"CLO_0002165","ATCC CRL-1550",Homo sapiens,cervix,,epithelial,,female,,,,"DOID:3744, cervical squamous cell carcinoma",,,none,,"COSS906824","STR-PCR Data (source: ECACC):
Amelogenin: X
CSF1PO: 10
D13S317: 8,12
D16S539: 11
D5S818: 13
D7S820: 8,11
THO1: 7
TPOX: 8
vWA: 17",adherent,"From MGH/CMT as specified by cell provider: RPMI 1640 + 2mM Glutamine + 10% Fetal Bovine Serum (FBS). Split confluent cultures 1:3 to 1:6 i.e. seeding at 2-4x10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37C.",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-484,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50007-1,50007,Ca9-22,,LCL-2033,"CLO_0051380","Japanese Collection of Research Bioresources Cell Bank JCRB0625",Homo sapiens,head & neck,,epithelial-like,,male,,,,"DOID:8602, malignant gingival tumor",gingival carcinoma,,none,,"COSS753538",,not specified,From MGH/CMT as specified by cell provider: EMEM w/ 0.6g/l glut and 10% FCS,,,,,,,,,,,2012-04-25,2016-07-12
50008-1,50008,CAL-51,,LCL-1472,"CLO_0002185","Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures ACC 302",Homo sapiens,breast,,epithelial-like,,female,,,,"DOID:3459, breast carcinoma",,,none,,"COSS910927",,adherent,From MGH/CMT as specified by cell provider: 80% Dulbecco's MEM (4.5 g/L glucose) + 20% FBS split culture 1:2 once or twice a week using trypsin/EDTA before cells reach complete confluency; seed out at ca. 2 x 106 cells/25 cm 2 ; cells may grow very slowly initially after thawing or after stringent trypsination at 37C with 5-10% CO2 cell harvest of ca. 15-20 x 106 cells/80 cm 2,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-450,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50009-1,50009,Calu-1,,LCL-1580,"CLO_0002191","ATCC HTB-54",Homo sapiens,lung,,epithelial,,male,,,,"DOID:3907, epidermoid lung carcinoma",NSCLC epidermoid lung carcinoma,,none,,,"DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 10
D13S317: 11,12
D16S539: 11
D5S818: 10,12
D7S820: 9,10
THO1: 9,9.3
TPOX: 8
vWA: 15,16",adherent,"From MGH/CMT as specified by cell provider: McCoy's 5a medium (modified) with 1.5 mM L-glutamine adjusted to contain 2.2 g/L sodium bicarbonate, 90%; fetal bovine serum, 10%",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-838,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50010-1,50010,Calu-3,,LCL-1631,"CLO_0002192","ATCC HTB-55",Homo sapiens,lung,,epithelial,,male,,,,"DOID:3910, lung adenocarcinoma",NSCLC adenocarcinoma,,none,,"COSS687777","DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 11,12
D13S317: 12
D16S539: 12,14
D5S818: 11
D7S820: 10,11
THO1: 6,9.3
TPOX: 8
vWA: 16,17",adherent,"From MGH/CMT as specified by cell provider: Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 90%; fetal bovine serum, 10%",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-798,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-04-04
50011-1,50011,COLO-679,,LCL-1232,"CLO_0002551","Cell Bank, RIKEN BioResource Center RCB0989",Homo sapiens,skin,,fibroblastic,,female,,,,"DOID:1909, malignant melanoma",,,none,,"COSS906818",,adherent,From MGH/CMT as specified by cell provider: 90-95% RPMI 1640 + 5-10% FBS split confluent culture 1:5 to 1:10 using trypsin/EDTA; change medium twice weekly; seed out at ca. 2 x 106 cells/80 cm 2 at 37C with 5% CO2 cell harvest of about 25 x 106 cells/175 cm 2,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-1025,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-04-04
50013-1,50013,FU97,,LCL-1894,"CLO_0037138","Japanese Collection of Research Bioresources Cell Bank JCRB1074",Homo sapiens,stomach,,epithelial-like,,female,,,,"DOID:5517, stomach carcinoma; DOID:3717, gastric adenocarcinoma",,,none,,"COSS1290806",,adherent,From MGH/CMT as specified by cell provider: Dulbecco's modified Eagle's medium (4.5g/L glucose) with 10% fetal calf serum and 10mg/L insulin,,,,,,,,,,,2012-04-25,2016-07-12
50014-1,50014,HEC-1,,LCL-1496,"CLO_0037162","Japanese Collection of Research Bioresources Cell Bank JCRB0042",Homo sapiens,uterus,,,,female,,,,"DOID:363, uterine cancer; DOID:1380, Endometrial cancer; DOID:2871, endometrial carcinoma; DOID:2870, endometrial adenocarcinoma",,,none,,"COSS907051",,not specified,JHSF growth medium: Eagle's minimal essential medium with 10% calf serum.,,,,,,,,,,,2012-04-25,2016-07-12
50015-1,50015,HLF,,LCL-1938,"CLO_0009987","Japanese Collection of Research Bioresources Cell Bank JCRB0405",Homo sapiens,liver,,,,male,,,,"DOID:684, hepatoma",hepatocellular carcinoma,,none,,,,adherent,From MGH/CMT as specified by cell provider: DMEM w/ 5% FBS,,,,,,,,,,,2012-04-25,2016-07-12
50018-1,50018,Ishikawa,,LCL-1497,"CLO_0037163","European Collection of Authenticated Cell Cultures (ECACC) 99040201",Homo sapiens,uterus,,epithelial-like,,female,,,,"DOID:363, uterine cancer; DOID:1380, Endometrial cancer; DOID:2871, endometrial carcinoma; DOID:2870, endometrial adenocarcinoma",,,none,,,"STR-PCR Data (source: ECACC):
Amelogenin: X
CSF1PO: 11,12
D13S317: 9,12
D16S539: 9
D5S818: 10,11
D7S820: 9,10
THO1: 9,10
TPOX: 8
vWA: 14,17",adherent,"ECACC growth medium: MEM + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 5% Foetal Bovine Serum (FBS). Subculture routine: Split sub-confluent cultures (70-80%) 1:5 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37 deg C; cells tend to pile up.",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-1111,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50019-1,50019,Ishikawa (Heraklio) 02 ER-,,LCL-1498,"CLO_0006967",European Collection of Authenticated Cell Cultures (ECACC) (discontinued),Homo sapiens,uterus,,epithelial,,female,,,,"DOID:363, uterine cancer; DOID:1380, Endometrial cancer; DOID:2871, endometrial carcinoma; DOID:2870, endometrial adenocarcinoma",,,none,,,,not specified,"From MGH/CMT as specified by cell provider: MEM + 10mM glutamine + 1% NEAA + 15% HI-FBS Split confluent cultures 1:8 i.e. seeding at 1-2 x 10,000 cells / cm2 using 0.25% trypsin or trypsin / EDTA; 5% CO2; 37C",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-1112,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50021-1,50021,JHH-6,,LCL-1923,"CLO_0009993","Japanese Collection of Research Bioresources Cell Bank JCRB1030",Homo sapiens,liver,,epithelial-like,,female,,,,"DOID:684, hepatocellular carcinoma",,,none,,"COSS1240159",,adherent,From MGH/CMT as specified by cell provider: William's E w/ 10% FCS,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-660,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50023-1,50023,KMRC-20,,LCL-1755,"CLO_0009978","Japanese Collection of Research Bioresources Cell Bank JCRB1071",Homo sapiens,kidney,,epithelial-like,,female,,,,"DOID:4450, renal cell adenocarcinoma",,,none,,"COSS1298169",,not specified,From MGH/CMT as specified by cell provider: Dulbecco's modified Eagle's medium with 10% fetal calf serum,,,,,,,,,,,2012-04-25,2016-07-12
50024-2,50024,KYSE-140,,LCL-1547,"CLO_0007128","Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures ACC 348",Homo sapiens,esophagus,,,,male,,,,"DOID:3748, esophageal squamous cell carcinoma",,,none,,"COSS753573",,adherent,"From MGH/CMT as specified by cell provider: 90% RPMI 1640 + 10% FBS split confluent culture 1:5 to 1:10 every 2-4 days using trypsin/EDTA (cells may need five or more minutes to detach from the flask; prior to using trypsin, cells should be washed twice with PBS); seed out at ca. 2-3 x 106 cells/80 cm 2 at 37C with 5% CO2 cell harvest of ca. 20-30 x 10 6 cells/175 cm 2",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-496,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50025-1,50025,KYSE-150,,LCL-1548,"CLO_0007129","Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures ACC 375",Homo sapiens,esophagus,,epithelioid,,female,,,,"DOID:3748, esophageal squamous cell carcinoma",,,none,,"COSS907317",,adherent,From MGH/CMT as specified by cell provider: 49% RPMI 1640 + 49% Ham's F12 + 2% FBS split confluent culture 1:20 every 3-4 days using trypsin/EDTA; seed out at ca. 1 x 106 cells/175 cm 2 at 37C with 5% CO2 cell harvest of ca. 1 x 105 cells/cm 2,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-497,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50027-1,50027,KYSE-450,,LCL-1550,"CLO_0007134","Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures ACC 387",Homo sapiens,esophagus,,epithelioid,,male,,,,"DOID:3748, esophageal squamous cell carcinoma",,,none,,"COSS907320",,adherent,From MGH/CMT as specified by cell provider: 45% RPMI 1640 + 45% Ham's F12 + 10% FBS split confluent culture 1:8 to 1:10 every 3-4 days using trypsin/EDTA; seed out at ca. 1 x 106 cells/25 cm 2 at 37 C with 5% CO2 cell harvest of ca. 5 x 106 cells/25 cm 2,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-502,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50028-1,50028,LNZTA3WT4,LNZTA3p53WT4; WT4,LCL-1345,"CLO_0007371","ATCC CRL-11543",Homo sapiens,brain,,,,unknown,,,,"DOID:3068, glioblastoma",,,none,,"COSS1240170","DNA Profile (STR, source: ATCC):
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11
D16S539: 9,12
D5S818: 12
D7S820: 10,12
THO1: 9.3
TPOX: 8,9
vWA: 15,17",adherent,"From MGH/CMT as specified by cell provider: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 1 microgram/ml tetracycline, 90%; heat-inactivated fetal bovine serum, 10%.
Subculturing: Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation ratio: A subcultivation ratio of 1:4 to 1:10 is recommended",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-344,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-04-04
50030-1,50030,MDA-MB-435S,,LCL-1307,"CLO_0007638","ATCC HTB-129",Homo sapiens,skin,,melanocyte,,female,,,,"DOID:1909, malignant melanoma (updated based on http://www.atcc.org/products/all/HTB-129.aspx)",,,none,,,"DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 11
D13S317: 12
D16S539: 13
D5S818: 12
D7S820: 8,10
THO1: 6,7
TPOX: 8,11
vWA: 16,18",adherent,"From MGH/CMT as specified by cell provider: Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 0.01 mg/ml insulin, 90%; fetal bovine serum, 10%.
Protocol: Remove medium, add fresh 0.25%trypsin - 0.053 mM EDTA, rinse and remove. Place flask at room temperature (or incubated at 37C) for approximately 10 minutes or until the cells detach. Add fresh medium, aspirate and dispense into new flasks.
Subcultivation ratio: A subcultivation ratio of 1:3 to 1:6 is recommended",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-419,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50031-1,50031,MT-3,,LCL-1473,"CLO_0007890","Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures ACC 403",Homo sapiens,breast,,epithelial,,female (probably),,,,"DOID:3459, breast carcinoma",,,none,,,,adherent as colonies,From MGH/CMT as specified by cell provider: 90% RPMI 1640 + 10% FBS + 2 mM L-glutamine + 1 mM sodium pyruvate split confluent culture 1:10 every 4-5 days using trypsin/EDTA; seed out at ca. 1 x 10 6 cells/25 cm 2 at 37C with 5% CO2 cell harvest of ca. 0.4 x 106 cells/cm 2,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-462,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50033-1,50033,NCI-H1651,H1651,LCL-1633,"CLO_0008008","ATCC CRL-5884",Homo sapiens,lung,,epithelial,,male,,,,"DOID:3910, lung adenocarcinoma",NSCLC adenocarcinoma,,none,,"COSS910900","DNA Profile (STR, source: ATCC): Amelogenin: X
CSF1PO: 10,13
D13S317: 11
D16S539: 11
D5S818: 12,14
D7S820: 8
THO1: 8
TPOX: 11
vWA: 18",adherent,"From MGH/CMT as specified by cell provider: ACL-4 medium supplemented with 10% FBS. ACL-4 medium is formulated at the ATCC as follows:
A 1:1 mixture of Ham's F12 medium with 2.5 mM L-glutamine and Dulbecco's Modified Eagle's Medium adjusted to contain 1.2 g/L sodium bicarbonate (available as ATCC 30-2006) with additional supplements at the concentrations below:
0.02 mg/ml insulin
0.01 mg/ml transferrin
25 nM sodium selenite
50 nM Hydrocortisone
1 ng/ml Epidermal Growth Factor (do not filter)
0.01 mM ethanolamine
0.01 mM phosphorylethanolamine
100 pM triiodothyronine
0.5% (w/v) bovine serum albumin
10 mM HEPES
0.5 mM sodium pyruvate
2mM L-glutamine",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-816,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-04-04
50035-1,50035,NCI-H1915,H1915,LCL-1598,"CLO_0008029","ATCC CRL-5904",Homo sapiens,lung,,large cell,,female,,,,"DOID:3908, non-small cell lung carcinoma",NSCLC carcinoma,,none,,"COSS1240184",,adherent,"From MGH/CMT as specified by cell provider: RPMI 1640 medium, 90%; fetal bovine serum, 10%",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-823,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-04-04
50036-1,50036,NCI-H2023,H2023,LCL-1599,"CLO_0008039","ATCC CRL-5912",Homo sapiens,lung,,,,male,,,,"DOID:3908, non-small cell lung carcinoma",NSCLC carcinoma,,none,,"COSS1240187","DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 12
D13S317: 12
D16S539: 11,12
D5S818: 12
D7S820: 11
THO1: 7,9
TPOX: 8
vWA: 18",not specified,"From MGH/CMT as specified by cell provider: HITES medium supplemented with 5% fetal bovine serum. HITES medium with 5% fetal bovine serum is formulated at the ATCC as follows:
Dulbecco's medium : Ham's F12, 50:50 mix (ATCC 30-2006)
Insulin 0.005 mg/ml
Transferrin 0.01 mg/ml
Sodium selenite 30 nM
Hydrocortisone 10 nM
beta-estradiol 10 nM
HEPES 10 mM
L-glutamine 2 mM (in addition to that in the base medium)
fetal bovine serum 5%",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-825,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50039-1,50039,PE/CA-PJ15,,LCL-1212,"CLO_0009951","European Collection of Authenticated Cell Cultures (ECACC) 96121230",Homo sapiens,head & neck,,epithelial-like,,unknown,,,,"DOID:1749, DOID:8649, tongue squamous carcinoma",,,none,,"COSS1240207",,adherent,"ECACC growth medium: IDMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS). Subculture routine: split sub-confluent cultures (70-80%) 1:2 to 1:8 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37 deg C. Note: cells may take up to 7 days to become confluent, a medium change during this period may be required.",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-546,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-08-24
50040-1,50040,PL4,,LCL-1098,"CLO_0037112",Cyril Benes (Massachusetts General Hospital),Homo sapiens,pancreas,,,,not specified,,,,"DOID:4905, pancreatic carcinoma",,,none,,"COSS1298533",,adherent,,,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-1134,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50044-1,50044,SK-OV-3,,LCL-1517,"CLO_0009063","ATCC HTB-77",Homo sapiens,ovary,,epithelial,,female,,,,"DOID:3713, ovarian adenocarcinoma",,,none,,"COSS905959","STR-PCR Data (source: ECACC):
Amelogenin: X
CSF1PO: 11
D13S317: 8,11
D16S539: 12
D5S818: 11
D7S820: 13,14
THO1: 9,9.3
TPOX: 8,11
vWA: 17,18",adherent,"From MGH/CMT as specified by cell provider: McCoy's 5a + 2mM Glutamine + 15% Fetal Bovine Serum (FBS). Split confluent cultures 1:2 to 1:3 i.e. seeding at 3-6x10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37C.",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-939,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50046-1,50046,SW527,SW 527; SW-527,LCL-1474,"CLO_0009219","ATCC CRL-7940",Homo sapiens,breast,,epithelial,,female,,,,"DOID:3459, breast carcinoma",,,none,,,,adherent,"From MGH/CMT as specified by cell provider: Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose, 90%; fetal bovine serum, 10%",,,,,,,,,,,2012-04-25,2016-07-12
50047-1,50047,SW620,SW-620,LCL-1157,"CLO_0009221","ATCC CCL-227",Homo sapiens,intestine,,epithelial,,male,,,,"DOID:1520, colon carcinoma","colon adenocarcinoma, Dukes' type C",,none,,"COSS905962","DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 13,14
D13S317: 12
D16S539: 9,13
D5S818: 13
D7S820: 8,9
THO1: 8
TPOX: 11
vWA: 16",adherent,"From MGH/CMT as specified by cell provider: Leibovitz's L-15 medium with 2 mM L-glutamine, 90%; fetal bovine serum, 10%",,,,,,,,,,,2012-04-25,2016-04-04
50048-1,50048,T24,T-24,LCL-1709,"CLO_0009245","ATCC HTB-4",Homo sapiens,urinary bladder,,epithelial,,female,,,,"DOID:4007, bladder carcinoma; DOID:4006, bladder transitional cell carcinoma",transitional cell carcinoma; urothelial bladder carcinoma,,none,,"COSS724812","DNA Profile (STR, source: ATCC):
Amelogenin: X
CSF1PO: 10,12
D13S317: 12
D16S539: 9
D5S818: 10,12
D7S820: 10,11
THO1: 6
TPOX: 8,11
vWA: 17",adherent,"From MGH/CMT as specified by cell provider: McCoy's 5a medium (modified) with 1.5 mM L-glutamine adjusted to contain 2.2 g/L sodium bicarbonate, 90%; fetal bovine serum, 10%.
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Subcultivation ratio: A subcultivation ratio of 1:3 to 1:8 is recommended",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-11,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12
50049-1,50049,WiDr,,LCL-1169,"CLO_0009600","ATCC CCL-218",Homo sapiens,intestine,,epithelial,,female,,,,"DOID:1520, DOID:234, colon adenocarcinoma",,,none,,,"STR-PCR Data (source: ECACC):
Amelogenin: X
CSF1PO: 11,12
D13S317: 11,12
D16S539: 11,12
D5S818: 11,12
D7S820: 10
THO1: 6,9
TPOX: 8,9
vWA: 17,19",adherent,"From MGH/CMT as specified by cell provider: EMEM (EBSS) + 2mM Glutamine + 1% Non Essential Amino Acids (NEAA) + 10% Fetal Bovine Serum (FBS). Split confluent cultures 1:5 to 1:10 i.e. seeding at 1-2x10,000 cells/cm2 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37C.",,,,Center for Molecular Therapeutics (CMT; Massachusetts General Hospital),MGH-602,,Obtained by Yangzhong Tang (Harvard Medical School) from the Center for Molecular Therapeutics (CMT; Massachusetts General Hospital) (contact: Cyril Benes).,,,,2012-04-25,2016-07-12